ERBB2 and breast cancer: Exosomes from SKBR3 and BT-474, both of which are HER2-overexpressing breast cancer cell lines, contain active HER2 and, along with exosomes from HER2-positive breast cancer patient serum, bound to trastuzumab to decrease the drugs' effectiveness at inhibiting SKBR3 cell proliferation [40].